Acute Pulmonary Embolism in Hemodynamically Stable Hospitalized Patients – Use of Systemic Thrombolysis
Systemic thrombolysis is reserved for patients who are hemodynamically stable but meet intermediate‑high‑risk criteria indicating a high probability of early adverse outcomes. Anticoagulation alone is appropriate for patients without these high‑risk features. Major bleeding contraindications must be assessed before thrombolysis is considered.
Risk Stratification and Indications for Systemic Thrombolysis
- Hemodynamic stability is defined as systolic blood pressure ≥ 90 mm Hg without vasopressor support [1][2].
- Intermediate‑high‑risk status requires evidence of right‑ventricular (RV) dysfunction on imaging (e.g., echocardiography or CT) and elevated cardiac biomarkers (troponin or BNP) [2].
- Patients meeting both RV dysfunction and biomarker elevation are candidates for systemic thrombolysis when the anticipated benefit outweighs bleeding risk [3].
Anticoagulation‑Only Management
- Patients who are hemodynamically stable and lack combined RV dysfunction plus biomarker elevation are managed with anticoagulation alone [2].
- Standard anticoagulant regimens (unfractionated heparin, low‑molecular‑weight heparin, or direct oral anticoagulants) are initiated promptly in this group [1].
Major Bleeding Contraindications to Systemic Thrombolysis
- Absolute contraindications include active intracranial hemorrhage, recent ischemic stroke, intracranial neoplasm, or recent major surgery/trauma with high bleeding risk.
- Relative contraindications encompass uncontrolled hypertension, recent gastrointestinal bleeding, or platelet count < 50 × 10⁹/L.
These contraindications are derived from established thrombolytic safety guidance and should be confirmed against the most current guideline recommendations.